28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC

Metastatic renal cell carcinoma (mRCC) has been one of the most treatment-resistant cancers because of its unpredictable clinical course, resistance to chemo- and radiotherapy, and the limited response to immunotherapy and targeted agents. We present a case of long-term survival, that is, 28 years,...

Descripción completa

Detalles Bibliográficos
Autores principales: Magdy, A., Bretterbauer, K., Hruby, S., Kunit, T., Colleselli, D., Janetschek, G., Mitterberger, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355604/
https://www.ncbi.nlm.nih.gov/pubmed/25810943
http://dx.doi.org/10.1155/2015/523258
_version_ 1782360885897986048
author Magdy, A.
Bretterbauer, K.
Hruby, S.
Kunit, T.
Colleselli, D.
Janetschek, G.
Mitterberger, M.
author_facet Magdy, A.
Bretterbauer, K.
Hruby, S.
Kunit, T.
Colleselli, D.
Janetschek, G.
Mitterberger, M.
author_sort Magdy, A.
collection PubMed
description Metastatic renal cell carcinoma (mRCC) has been one of the most treatment-resistant cancers because of its unpredictable clinical course, resistance to chemo- and radiotherapy, and the limited response to immunotherapy and targeted agents. We present a case of long-term survival, that is, 28 years, after primary diagnosis (longest survival in the literature up to our knowledge) with mRCC after several metastasectomies (from local site recurrence, liver, and lung) and eight lines of systemic targeted therapy. This case report shows how crucial is the regular follow-up of patients with RCC after primary management and positive impact of early metastasectomy and systemic targeted therapy in case of mRCC on patients' condition and overall survival.
format Online
Article
Text
id pubmed-4355604
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43556042015-03-25 28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC Magdy, A. Bretterbauer, K. Hruby, S. Kunit, T. Colleselli, D. Janetschek, G. Mitterberger, M. Case Rep Urol Case Report Metastatic renal cell carcinoma (mRCC) has been one of the most treatment-resistant cancers because of its unpredictable clinical course, resistance to chemo- and radiotherapy, and the limited response to immunotherapy and targeted agents. We present a case of long-term survival, that is, 28 years, after primary diagnosis (longest survival in the literature up to our knowledge) with mRCC after several metastasectomies (from local site recurrence, liver, and lung) and eight lines of systemic targeted therapy. This case report shows how crucial is the regular follow-up of patients with RCC after primary management and positive impact of early metastasectomy and systemic targeted therapy in case of mRCC on patients' condition and overall survival. Hindawi Publishing Corporation 2015 2015-02-25 /pmc/articles/PMC4355604/ /pubmed/25810943 http://dx.doi.org/10.1155/2015/523258 Text en Copyright © 2015 A. Magdy et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Magdy, A.
Bretterbauer, K.
Hruby, S.
Kunit, T.
Colleselli, D.
Janetschek, G.
Mitterberger, M.
28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
title 28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
title_full 28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
title_fullStr 28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
title_full_unstemmed 28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
title_short 28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
title_sort 28-year survival following several metastasectomies, going through 8th line systemic therapy in a case of mrcc
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355604/
https://www.ncbi.nlm.nih.gov/pubmed/25810943
http://dx.doi.org/10.1155/2015/523258
work_keys_str_mv AT magdya 28yearsurvivalfollowingseveralmetastasectomiesgoingthrough8thlinesystemictherapyinacaseofmrcc
AT bretterbauerk 28yearsurvivalfollowingseveralmetastasectomiesgoingthrough8thlinesystemictherapyinacaseofmrcc
AT hrubys 28yearsurvivalfollowingseveralmetastasectomiesgoingthrough8thlinesystemictherapyinacaseofmrcc
AT kunitt 28yearsurvivalfollowingseveralmetastasectomiesgoingthrough8thlinesystemictherapyinacaseofmrcc
AT collesellid 28yearsurvivalfollowingseveralmetastasectomiesgoingthrough8thlinesystemictherapyinacaseofmrcc
AT janetschekg 28yearsurvivalfollowingseveralmetastasectomiesgoingthrough8thlinesystemictherapyinacaseofmrcc
AT mitterbergerm 28yearsurvivalfollowingseveralmetastasectomiesgoingthrough8thlinesystemictherapyinacaseofmrcc

Ejemplares similares